Fulgent Genetics (NASDAQ:FLGT) Issues Earnings Results, Beats Estimates By $0.56 EPS

by · The Cerbat Gem

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) announced its earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.56, FiscalAI reports. The firm had revenue of $90.41 million during the quarter, compared to analyst estimates of $86.30 million. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%.

Here are the key takeaways from Fulgent Genetics’ conference call:

  • Third-quarter revenue rose 8% year over year to $90.4 million, with Anatomic Pathology up 57% and BioPharma Services up 5%; growth was primarily driven by the integration of Bako and StrataDx. Precision Diagnostics declined 18% year over year.
  • Management reported improving collections after billing-system customizations helped lift third-quarter revenue and gross margin sequentially. The transition is not complete, however, and management said further work is needed before collections return to historical levels.
  • Fulgent narrowed its 2026 non-GAAP loss-per-share outlook to $1.65–$1.75 from $2.22–$2.35, and raised its projected year-end cash, restricted cash, and marketable securities to about $630 million. The cash increase chiefly reflects a $112.3 million federal tax refund and related interest.
  • The company reported progress in its oncology pipeline: FID-007’s Phase II is mostly complete, with a Phase III study in preparation, while FID-022 is in Phase I dose escalation. These programs remain clinical-stage and their commercial prospects are uncertain.
  • Fulgent’s AI platform analyzed about 255,000 slide images in Q3, up 23% sequentially, and analysis failures fell to 0.01%; five additional AI applications are planned for Q4. Management said the technology could improve quality and productivity, though it did not quantify a current financial benefit.

Fulgent Genetics Stock Performance

Fulgent Genetics stock traded up $5.08 during mid-day trading on Friday, reaching $23.74. The company’s stock had a trading volume of 1,097,340 shares, compared to its average volume of 274,766. The company has a market capitalization of $653.09 million, a price-to-earnings ratio of -7.68 and a beta of 1.00. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04. The business’s 50 day simple moving average is $20.80 and its 200 day simple moving average is $19.31.

Insider Buying and Selling at Fulgent Genetics

In other news, COO Jian Xie sold 2,127 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total transaction of $41,816.82. Following the completion of the transaction, the chief operating officer directly owned 359,924 shares in the company, valued at $7,076,105.84. This represents a 0.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,673 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total value of $32,891.18. Following the completion of the transaction, the insider owned 986,117 shares of the company’s stock, valued at $19,387,060.22. The trade was a 0.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,932 shares of company stock worth $117,156 over the last quarter. Company insiders own 36.18% of the company’s stock.

Analyst Ratings Changes

FLGT has been the topic of a number of research reports. Weiss Ratings upgraded Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Piper Sandler upped their price objective on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.50.

Get Our Latest Analysis on Fulgent Genetics

About Fulgent Genetics

(Get Free Report)

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.

Read More